- Worldwide, about one out of every five cases of acute gastroenteritis is associated with norovirus. Norovirus is responsible for approximately 685 million cases of gastroenteritis every year.
- Globally, norovirus is estimated to cause approximately 200,000 deaths annually, with at least 70,000 being children in developing countries.
- There are currently two drug candidates in Phase II, but no candidates in Phase III. The majority of drug candidates currently in the pipeline for norovirus are vaccines. These drugs are administered via oral, intranasal, and intramuscular routes.
- The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for norovirus have been in the early and mid-phases of development, with 92.5% of trials in Phase I-II, and only 7.5% in Phase III.
- Clinical trial activity in the norovirus space is dominated by planned trials. Takeda has the highest number of planned clinical trials for norovirus, with 10 trials.
- Takeda leads industry sponsors with by far the highest number of clinical trials for norovirus, followed by Vaxart and UMN Pharma.
Challenges for vaccine development
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
List of Figures
Figure 1: Overview of pipeline drugs for norovirus in the US
Figure 2: Pipeline drugs for norovirus, by company
Figure 3: Pipeline drugs for norovirus, by drug type
Figure 4: Pipeline drugs for norovirus, by classifications
Figure 5: Clinical trials in norovirus
Figure 6: Top 10 drugs for clinical trials in norovirus
Figure 7: Top 10 companies for clinical trials in norovirus
Figure 8: Norovirus trials status
Figure 9: Norovirus trials sponsors, by phase
List of Tables
Table 1: Pipeline drugs for norovirus in the US